Lolamicin
Lolamicin is an orally effective inhibitor that specifically targets the Gram-negative bacteria lipoprotein transport system LolCDE complex. It selectively inhibits the transmembrane transport of outer membrane lipoproteins by competitively binding to lipoprotein binding sites. Lolamicin destroys the integrity of the bacterial outer membrane, leading to cell death, and has both bactericidal and antibacterial activity. It has significant effects on multidrug-resistant Enterobacteriaceae pathogens (such as Escherichia coli and Klebsiella pneumoniae) . Lolamicin can be used to inhibit the study of acute pneumonia, sepsis and other infections caused by Gram-negative bacteria[1].
Product Specifications
CAS Number
2930690-12-1
UNSPSC
12352005
Target
Antibiotic; Bacterial
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/lolamicin.html
Concentration
10mM
Purity
99.54
Solubility
DMF : ≥ 100 mg/mL|DMSO : 175 mg/mL (ultrasonic)
Smiles
N#CC1=CC=CC(COC2=CC=CC(C3=NNC=C3C4=CC(C)=NC(C)=C4)=C2)=C1
Molecular Formula
C24H20N4O
Molecular Weight
380.44
References & Citations
[1]Muñoz K A, et al. A Gram-negative-selective antibiotic that spares the gut microbiome[J]. Nature, 2024: 1-8.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Cytokeratin 8 (KRT8) (KRT8/2174R), CF568 conjugate, 0.1mg/mL
alpha A Crystallin (CRYAA) Human Gene Knockout Kit (CRISPR)
